5-(3-fluorophenyl)thiophene-2-carbaldehyde

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(3-fluorophenyl)thiophene-2-carbaldehyde
• 化学式: C₁₁H₇FOS
• mdl: MFCD06410180
• 分子量: 206.24
• InChiKey: AMTYNYZDGZBISY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-硫代乙内酰脲 、 5-(3-fluorophenyl)thiophene-2-carbaldehyde 在 溶剂黄146 、 β-丙氨酸 作用下， 反应 15.0h， 以75%的产率得到5-((5-(3-fluorophenyl)thiophen-2-yl)methylene)-2-thioxoimidazolidin-4-one
  参考文献：
  名称：

  Exploration of a Series of 5-Arylidene-2-thioxoimidazolidin-4-ones as Inhibitors of the Cytolytic Protein Perforin

  摘要：

  A series of novel 5-arylidene-2-thioxoimidazolidin-4-ones were investigated as inhibitors of the lymphocyte-expressed pore-forming protein perform. Structure activity relationships were explored through variation of an isoindolinone or 3,4-dihydroisoquinolinone subunit on a fixed 2-thioxoimidazolidin-4-one/thiophene core. The ability of the resulting compounds to inhibit the lytic activity of both isolated perform protein and perforin delivered in situ by natural killer cells was determined. A number of compounds showed excellent activity at concentrations that were nontoxic to the killer cells, and several were a significant improvement on previous classes of inhibitors, being substantially more potent and soluble. Representative examples showed rapid and reversible binding to immobilized mouse perforin at low concentrations (<= 2.5 mu M) by surface plasmon resonance and prevented formation of perforin pores in target cells despite effective target cell engagement, as determined by calcium influx studies. Mouse PK studies of two analogues showed T-1/2 values of 1.1-1.2 h (dose of 5 mg/kg iv) and MTDs of 60-80 mg/kg (ip).

  DOI：

  10.1021/jm401604x
• 作为产物：
  描述：

  2-噻吩甲醛 、 间溴氟苯 在 potassium acetate 、 C₄₂H₄₅Cl₂N₃Pd 、 三甲基乙酸 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 24.0h， 以90%的产率得到5-(3-fluorophenyl)thiophene-2-carbaldehyde
  参考文献：
  名称：

  双(亚氨基)苊 (BIAN) 负载的具有辅助配体的 N-杂环卡宾钯配合物：用于噻吩直接 C-H 芳基化的易活化预催化剂

  摘要：

  我们在此报告了通过庞大的双（亚氨基）苊（BIAN）负载的N将噻吩与（杂）芳基溴化物的高效直接 C-H 芳基化-杂环卡宾钯配合物。讨论了钯与辅助配体的结构与催化性能之间的关系。在 0.01-0.05 mol% 的低钯负载量下，庞大的钯络合物成功地用于在有氧条件下催化各种噻吩与（杂）芳基溴化物的交叉偶联。此外，它提供了一种在好氧反应条件下获得具有高分子量和高 HT 值的聚 (3-己基噻吩) 的实用且直接的途径。为了了解转化机制，对直接芳基化进行了实验研究和 DFT 计算，这支持了 Pd (0) /Pd (II) CMD 过程的参与。

  DOI：

  10.1021/acs.organomet.2c00007

文献信息

• Propionic Acid Derivatives and Methods of Use Thereof
  申请人：Biediger Ronald J.

  公开号：US20180312523A1

  公开（公告）日：2018-11-01

  Provided herein are compounds and pharmaceutical compositions of formula I where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

  本文提供了公式I的化合物和药物组合物，其中R1、R2、R3、R4、R5和R6如本文所述。还提供了这些化合物的药用可接受盐或立体异构体。此外，还提供了用于抑制整合素结合以治疗各种病理生理条件的方法。
• [EN] COMPOUNDS, PREPARATIONS AND USES THEREOF<br/>[FR] COMPOSÉS, LEURS PRÉPARATIONS ET LEURS UTILISATIONS
  申请人：PETER MACCALLUM CANCER INST

  公开号：WO2011075784A1

  公开（公告）日：2011-06-30

  The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as agents or drugs for inhibiting perforin activity and for treating a subject at risk of or susceptible to a disease or disorder, or having a disease or disorder associated with undesirable perforin activity.

  本发明提供了式（I）的新化合物，包括这些化合物的药物组合物以及使用这些化合物作为抑制穿孔素活性的药剂或药物，用于治疗患有与不良穿孔素活性相关的疾病或紊乱、或处于患有风险或易感染某种疾病或紊乱的受试者的方法。
• COMPOUNDS, PREPARATION AND USES THEREOF
  申请人：Spicer Julie Ann

  公开号：US20130065897A1

  公开（公告）日：2013-03-14

  The present invention provides novel compounds of the Formula I, pharmaceutical compositions comprising such compounds and methods for using such compounds as agents or drugs for inhibiting perforin activity and for treating a subject at risk of or susceptible to a disease or disorder, or having a disease or disorder associated with undesirable perforin activity.

  本发明提供了公式I的新化合物，包括这些化合物的制药组合物以及使用这些化合物作为抑制穿孔素活性的药剂或药物的方法，以及用于治疗处于风险或易感疾病或紊乱，或具有与不良穿孔素活性相关的疾病或紊乱的受试者。
• Discovery of thiophen-2-ylmethylene bis-dimedone derivatives as novel WRN inhibitors for treating cancers with microsatellite instability
  作者：Hwasun Yang、Miso Kang、Seonyeong Jang、Soo Yeon Baek、Jiwon Kim、Gyeong Un Kim、Dongwoo Kim、Junsu Ha、Jong Seung Kim、Cheulhee Jung、Nam-Jung Kim、Sung-Yup Cho、Woong-Hee Shin、Juyong Lee、Junsu Ko、Ansoo Lee、Gyochang Keum、Sanghee Lee、Taek Kang

  DOI：10.1016/j.bmc.2024.117588

  日期：2024.2

  various cancer types. Recent research has identified Werner syndrome ATP-dependent helicase (WRN) as a promising synthetic lethal target for MSI cancers. Herein, we report the first discovery of thiophen-2-ylmethylene bis-dimedone derivatives as novel WRN inhibitors for MSI cancer therapy. Initial computational analysis and biological evaluation identified a new scaffold for a WRN inhibitor. Subsequent

  微卫星不稳定性 (MSI) 是一种由 DNA 错配修复系统缺陷引起的高突变状态，导致各种癌症类型的发展。最近的研究已确定维尔纳综合征 ATP 依赖性解旋酶 (WRN) 是 MSI 癌症的一个有前景的合成致死靶点。在此，我们报告了首次发现噻吩-2-基亚甲基双二甲酮衍生物作为用于 MSI 癌症治疗的新型 WRN 抑制剂。初步计算分析和生物学评估确定了 WRN 抑制剂的新支架。随后的 SAR 研究发现了一种高效的 WRN 抑制剂。此外，我们证明最佳化合物通过抑制 WRN 诱导 MSI 癌细胞 DNA 损伤和细胞凋亡。这项研究为 WRN 抑制剂提供了一种新的药效团，强调了它们对 MSI 癌症的治疗潜力。
• Propionic acid derivatives and methods of use thereof
  申请人：Biediger Ronald J.

  公开号：US10875875B2

  公开（公告）日：2020-12-29

  Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

  本文提供了式 I 的化合物和药物组合物 其中 R1、R2、R3、R4、R5 和 R6 如本文所述。还提供了这些化合物的药学上可接受的盐或立体异构体。此外，还提供了抑制整合素结合以治疗各种病理生理状况的方法。